Company Overview
ADC Therapeutics SA operates within the healthcare sector, specifically functioning as a biotechnology company dedicated to providing an antibody drug conjugate technology platform across Switzerland and the United States. The company's primary focus includes its flagship product, ZYNLONTA, which is a CD19-directed ADC that has secured accelerated approval from the U.S. Food and Drug Administration alongside conditional approval from the European Commission. This specialized operational model positions the firm as a mid-sized entity with a market capitalization of $504.37M and an annual revenue of $81.36M, supported by a workforce of 188 employees. These financial dimensions indicate that the company is an established player in the biotechnology landscape, yet its valuation and revenue scale suggest it is still in a phase of development where significant capital allocation is required to sustain R&D efforts and commercial expansion rather than generating substantial free cash flow.
Financial Health
The company reported a revenue of $81.36M over the trailing twelve months, though this top-line performance is accompanied by a net income of $-142,623,008 and an EBITDA of $-105,390,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs typical of the biotechnology industry before products achieve full commercial maturity. Despite the negative earnings, the firm maintains a cash balance of $261.34M, while simultaneously carrying a debt load of $439.55M, resulting in a free cash flow of $-103,812,000. The negative free cash flow indicates that the company is currently burning cash to fund its operations and growth initiatives, which limits immediate financial flexibility but is a common strategy for early-stage commercialization in the sector. When analyzing profitability metrics, the gross margin stands at -32.2%, the operating margin at -69.3%, and the profit margin at -175.3%, all of which reflect the intense upfront investment required to bring specialized therapies to market. The balance sheet presents a leveraged profile, as the total debt of $439.55M exceeds the cash reserves of $261.34M, although the absence of a debt-to-equity ratio suggests the equity base may not be sufficient to cover debt without dilution or refinancing. Liquidity is managed through a current ratio of 4.37, which indicates that the company possesses more than four times the current assets needed to cover its short-term liabilities. Finally, the return on equity is listed as N/A due to the lack of positive retained earnings relative to equity, while the return on assets is -20.6%, signaling that management is currently generating negative returns on the asset base as the company transitions toward profitability.
Valuation Assessment
The valuation metrics for ADC Therapeutics SA present a complex picture, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -2.66. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings expectations that are currently obscured by the company's present losses, suggesting a trajectory where profitability is anticipated but not yet realized in the historical record. Additionally, the price-to-book ratio is -2.69, which indicates a market premium or discount relative to book value that is distorted by the company's negative equity position, rendering the traditional P/B metric less meaningful for valuation purposes. Investors looking at alternative metrics find a price-to-sales ratio of 6.20 and an EV/EBITDA of -6.48, which suggest that the company is being valued primarily on its revenue generation potential rather than its current earnings power or cash flow generation. Regarding price action, the stock has traded between a 52-week high of $4.98 and a 52-week low of $1.05, meaning the current price sits within this established volatility range. The beta value of 1.97 indicates that the stock's price volatility is significantly higher than the broader market, moving nearly twice as much as the benchmark index during periods of market fluctuation.
Growth & Income
ADC Therapeutics SA has demonstrated strong top-line expansion with a revenue growth of 36.4% year-over-year, whereas earnings growth is listed as N/A due to the company's continued unprofitability. The disparity between the robust revenue growth and the absence of positive earnings growth implies that the company is prioritizing market capture and R&D progress over immediate profitability, a common dynamic in the biotechnology sector. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a strategy where earnings are not distributed to shareholders but are instead retained to fund operations and growth initiatives. This reinvestment approach is typical for firms in the healthcare sector that require continuous capital injection to advance their pipeline, meaning the overall growth and income profile is defined by aggressive revenue expansion funded by cash reserves and debt rather than shareholder distributions.